Editas Medicine (0IFK.L) Stock Price
$2.2 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
0 -
Technical
5
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Editas Medicine, AI stock picks, stock alerts and much more.
0IFK.L AI Stock Analysis
AI stock analysis for 0IFK.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Editas Medicine (0IFK.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Editas Medicine (0IFK.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Editas Medicine (0IFK.L), currently trading at $2.2, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About 0IFK.L
-
Editas Medicine, Inc.
-
Symbol
0IFK.L
-
Market
LSE
-
Industry
Medical - Pharmaceuticals
-
Market Cap
168.4M
Similar Stocks
 |
Vertex Pharmaceuticals Incorporated 0QZU.L |
$439.9 1.9% |
7 |
 |
Neurocrine Biosciences 0K6R.L |
$126.5 0.2% |
7 |
 |
Emergent BioSolutions Inc. 0IGA.L |
$6.31 0% |
4 |
 |
Abeona Therapeutics Inc. 0H7R.L |
$5.84 4.2% |
5 |
 |
Walgreens Boots Alliance 0LSZ.L |
$11.35 0.4% |
4 |
News
0IFK.L Alternative Data
Web Traffic
Editas Medicine receives an estimated 14635 monthly visitors to editasmedicine.com.
-
Web Traffic
14635
-
Change from Previous Month
48.5%
-
3 Month Change
35.9%
-
YoY Change
35.9%
Twitter Followers
Editas Medicine has 8,256 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.
-
Twitter Followers
8256
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
0.5%
Instagram Followers
Editas Medicine has 29 Instagram Followers on its main Instagram account.
-
Instagram Followers
29
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Job Postings
Editas Medicine currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
-
YoY Change
100%
Reddit Mentions
Editas Medicine has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
48,823 are following Editas Medicine on LinkedIn, up by 0.5% over the last month.
-
LinkedIn Followers
48823
-
Daily Change
0.5%
-
1 Month Change
0.5%
-
3 Month Change
1.9%
-
YoY Change
1.9%
LinkedIn Employees
According to LinkedIn, Editas Medicine has 258 employees, down by -3.4% over the last month.
-
LinkedIn Employees
258
-
Daily Change
3.4%
-
1 Month Change
3.4%
-
3 Month Change
18.6%
-
YoY Change
18.6%
Business Outlook
According to employee reviews, the business outlook among employees at Editas Medicine is 60 out of 100 (neutral).
-
Business Outlook
60
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
News Mentions
Editas Medicine was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
-
YoY Change
100%
0IFK.L Financials
0IFK.L Key Metrics
-
Total Revenue
$30.6M
-
Net Income
-$45.4M
-
Earnings per Share
-$0.55
-
Free cash flow
-$51.3M
-
EBITDA
-$33M
-
EBITDA Ratio
-1.07764
-
Total Assets
$263.7M
0IFK.L 2-year Revenue & Income
0IFK.L 2-year Free Cash Flow
0IFK.L Technicals
0IFK.L SMA
0IFK.L RSI
FAQ
What's the current price of Editas Medicine (0IFK.L) Stock?
The price of an Editas Medicine (0IFK.L) share is $2.2.
What's the market cap of Editas Medicine?
The current market cap of Editas Medicine is 168.4M.
Should I buy or sell 0IFK.L?
Editas Medicine shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Editas Medicine is better viewed as a hold or accumulate position while waiting for further developments.
Is Editas Medicine a good investment?
The current analysis of Editas Medicine's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Editas Medicine's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Editas Medicine (0IFK.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Editas Medicine stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Editas Medicine (0IFK.L) that investors often compare it to?
Editas Medicine (0IFK.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Walgreens Boots Alliance.
What is the forecast for Editas Medicine's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Editas Medicine's stock price to be around $2.19 in 2026. Starting from the current price of $2.2, this represents a 0.7% change in price, indicating a neutral outlook for the stock.
How to buy Editas Medicine (0IFK.L) Stock?
Editas Medicine stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Editas Medicine shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.